Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Corgenix gets grant to develop Ebola and Marburg virus tests

This article was originally published in Clinica

Executive Summary

The US National Institutes of Health has awarded IVD firm Corgenix Medical a $600,000 grant to help develop tests for two tropical viruses: Ebola and Marburg. The grant will support a two-year study, which Corgenix expects to aid the development of “specific, cost-effective and easy-to-use tests” for both viruses. These could eventually lead to vaccines and treatments, the Denver, Colorado company hopes. Several other institutions are collaborating on the project, including Tulane University in New Orleans, Louisiana, and The Scripps Research Institute in La Jolla, California. Both the Ebola and Marburg viruses are found in Africa and cause haemorrhagic fevers, characterised by bleeding and coagulation abnormalities. Ebola is fatal in up to 90% of cases.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT081923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel